FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, and MOTS-C Despite Agency Scientists' Opposition An FDA advisory committee voted narrowly on July 23, 2026, to recommend that compounding pharmacies gain access to several popular peptide compounds, including BPC-157, KPV, TB-500, and MOTS-C, overriding explicit objections from the FDA's own career scientists and sparking an audible gasp in the meeting room when the tally was announced
Can I take tirzepatide every two weeks instead of weekly
Do not automatically repeat the dose
To better understand how the field is evolving and where it might go next DDN spoke with Jan Jezek, Chief Scientific Officer at Arecor Therapeutics, about the scientific challenges, delivery innovations, and future opportunities surrounding GLP-1 therapies
While these results need more independent replication, they support the idea of recurring cycles to sustain benefits
Bowler RP: Oxidative stress in the pathogenesis of asthma